recent
evid
suggest
associ
inflammatori
bowel
diseas
ibd
human
cytomegaloviru
hcmv
infect
exact
pathogen
role
hcmv
diseas
remain
unclear
hcmv
infect
long
time
known
associ
variou
autoimmun
manifest
format
autoantibodi
previou
studi
group
shown
hcmv
associ
human
protein
aminopeptidas
n
autoantibodi
protein
frequent
found
hcmv
infect
bone
marrow
transplant
patient
chronic
graft
versu
host
diseas
recent
observ
ibd
patient
activ
hcmv
infect
studi
examin
presenc
cytotox
autoantibodi
sera
obtain
patient
ulcer
coliti
patient
crohn
diseas
sera
obtain
healthi
blood
donor
use
flow
cytometr
assay
mous
cell
transfect
human
microcytotox
assay
differ
posit
human
cell
cytotox
autoantibodi
identifi
sera
obtain
hcmvigg
posit
patient
ulcer
coliti
sera
obtain
hcmvigg
posit
patient
crohn
diseas
control
individu
cytotox
autoantibodi
may
interfer
biolog
cell
function
could
therebi
contribut
chronic
inflamm
patient
ibd
human
cytomegaloviru
hcmv
belong
herpesvirida
famili
highli
preval
popul
world
like
herpesvirus
hcmv
establish
latenc
viru
frequent
reactiv
immunosuppress
patient
transplant
patient
hiv
infect
patient
reinfect
new
genet
distinct
hcmv
strain
observ
transplant
recipi
suggest
previous
establish
hcmv
infect
patient
protect
reinfect
immunocompromis
host
primari
reactiv
hcmv
infect
result
varieti
clinic
manifest
sometim
viru
caus
lifethreaten
hcmv
diseas
hcmv
diseas
gastrointestin
gi
tract
major
caus
morbid
mortal
immunocompromis
patient
hcmv
gi
diseas
often
suspect
aid
patient
gi
symptom
last
four
decad
increas
evid
also
suggest
hcmv
may
preval
patient
inflammatori
bowel
diseas
ibd
exact
pathogen
role
hcmv
diseas
develop
remain
uncertain
previous
provid
evid
high
preval
hcmvdna
hcmv
antigen
intestin
tissu
section
obtain
patient
ibd
suggest
common
presenc
activ
hcmv
infect
patient
also
previous
shown
hcmv
reactiv
latenc
macrophag
involv
inflammatori
cytokin
suggest
viral
reactiv
occur
inflammatori
tissu
increas
number
intestin
macrophag
often
observ
activ
ibd
especi
promin
granuloma
often
observ
bowel
patient
crohn
diseas
gener
agreement
autoimmun
diseas
multifactori
etiolog
depend
genet
environment
factor
among
latter
virus
may
play
import
role
sinc
induc
autoimmun
sever
mechan
exposur
normal
hidden
epitop
present
crossreact
peptid
upregul
key
molecul
antigen
present
cell
molecular
mimicri
mechan
present
host
cellderiv
protein
viral
envelop
hcmv
infect
suggest
associ
variou
autoimmun
manifest
hemolyt
anemia
granulocytopenia
autoimmun
like
diseas
chronic
graft
versu
host
diseas
gvhd
bone
marrow
transplant
patient
bmt
product
varieti
autoantibodi
group
previous
shown
cellular
molecul
becom
associ
hcmv
particl
viral
particl
matur
infect
cell
hcmvassoci
autoantigen
appear
becom
immunogen
hcmv
infect
support
hypothesi
previous
found
autoantibodi
bone
marrow
transplant
bmt
patient
activ
hcmv
infect
antibodi
may
bind
cell
posit
patient
tissu
endotheli
cell
smooth
muscl
cell
granulocyt
macrophag
may
exert
cytotox
effect
may
also
affect
import
cellular
function
varieti
immun
abnorm
describ
intestin
ibd
patient
antibodi
sever
differ
cell
type
neutrophil
granulocyt
endotheli
epitheli
inflammatori
smooth
muscl
cell
report
patient
ulcer
coliti
uc
crohn
diseas
cd
antibodi
suggest
play
pathogen
role
ibd
therefor
examin
preval
cytotox
effect
autoantibodi
direct
sera
obtain
patient
uc
cd
sera
collect
patient
activ
uc
sera
came
patient
uc
previous
examin
presenc
hcmv
patient
activ
cd
sera
came
patient
cd
previous
examin
presenc
hcmv
colonoscopi
clinic
radiolog
histolog
criteria
use
establish
diagnosi
case
tabl
twenti
patient
sever
uc
patient
sever
cd
respond
convent
medic
treatment
underw
surgeri
sera
obtain
healthi
blood
donor
serv
control
detect
presenc
igg
antibodi
intestin
tissu
paraffinembed
intestin
tissu
section
obtain
patient
uc
patient
cd
sampl
uninflam
intestin
tissu
tumorfre
resect
end
bowel
patient
intestin
tumor
use
neg
control
previous
examin
presenc
hcmv
cell
acut
monocyt
leukemia
cell
line
american
type
cultur
collect
rockvil
md
usa
maintain
bicarbonatefre
medium
supplement
mm
hepe
ethanesulfon
acid
heat
inactiv
fetal
calf
serum
lglutamin
mm
penicillin
uml
streptomycin
mgml
gibco
brl
grand
island
ny
usa
transfect
express
human
aminopeptidas
n
cell
surfac
kindli
provid
look
st
jude
children
research
hospit
memphi
tn
usa
cell
maintain
bicarbonatefre
minim
essenti
medium
hank
salt
gibco
brl
includ
supplement
addit
mg
geneticin
gibco
brl
per
ml
human
pulmonari
arteri
endotheli
cell
hpaec
clonet
cultur
c
co
medium
clonet
ca
usa
contain
growth
factor
accord
manufactur
instruct
cell
obtain
american
type
cultur
collect
cultur
c
atmospher
co
complet
medium
dulbecco
modifi
essenti
medium
gibco
brl
contain
fetal
bovin
serum
supplement
mm
lglutamin
penicillin
uml
streptomycin
mgml
neutrophil
leukocyt
isol
human
peripher
blood
healthi
donor
accord
et
al
briefli
ml
heparin
whole
blood
layer
gradient
consist
ml
overlay
ml
centrifug
min
g
room
temperatur
band
rich
polymorphonuclear
cell
collect
contamin
erythrocyt
remov
hypoton
lysi
cell
wash
twice
krebsring
phosphat
buffer
without
mg
ca
resuspend
krg
monoclon
antibodi
wm
dakopatt
glostrup
denmark
use
posit
control
flow
cytometri
fac
follow
mous
monoclon
antibodi
use
block
assay
becton
dickinson
stockholm
sweden
dakopatt
beckman
coulter
ca
usa
dakopatt
flow
cytometr
investig
mous
cell
transfect
mous
cell
incub
ml
patient
serum
preabsorb
cell
remov
natur
antibodi
min
room
temperatur
rt
cell
wash
pb
incub
fluorescein
fitc
goat
antihuman
igg
dakopatt
antibodi
separ
min
c
cell
wash
twice
resuspend
pb
analyz
fac
mous
transfect
mous
cell
incub
f
ab
fragment
mous
monoclon
antibodi
h
rt
cell
wash
incub
sera
preabsorb
cell
remov
natur
antibodi
follow
fitc
conjug
antibodi
cell
thereaft
analyz
flow
cytometri
criterion
chosen
posit
inhibit
reduct
least
channel
mean
fluoresc
compar
control
sera
screen
presenc
cytotox
antibodi
direct
cell
fresh
neutrophil
granulocyt
cell
hpaec
triplic
cytotox
detect
rabbit
complement
dye
acridin
orang
sigmaealdrich
stockholm
sweden
ethidium
bromid
ad
sera
ad
cell
result
cytotox
assay
evalu
invert
fluoresc
microscop
dead
cell
versu
aliv
cell
count
express
percentag
block
assay
perform
incub
cell
fresh
neutrophil
granulocyt
hpaec
f
ab
fragment
mous
monoclon
antibodi
h
rt
f
ab
fragment
obtain
treatment
pepsin
mgml
igg
h
c
follow
dialyz
acet
buffer
ph
h
c
reaction
stop
ad
tri
digest
protein
thereaft
dialyz
pb
night
f
ab
fragment
separ
clean
fc
fragment
incub
protein
h
c
f
ab
fragment
antibodi
obtain
way
serv
control
sera
ad
cell
result
quantifi
describ
investig
presenc
igg
antibodi
sera
ibd
patient
ml
tenfold
dilut
serum
incub
unfix
fresh
neutrophil
granulocyt
hpaec
min
c
wash
bound
antibodi
identifi
incub
fitc
conjug
goat
antihuman
igg
antibodi
dakopatt
cell
spot
slide
use
cytocentrifug
cytospin
shandon
southern
product
ltd
runcorn
uk
fix
cold
cytofix
dakopatt
examin
fluoresc
microscop
investig
whether
antibodi
patient
sera
react
perform
block
experi
unfix
cell
fresh
neutrophil
granulocyt
cell
hpaec
incub
f
ab
fragment
mixtur
two
monoclon
antibodi
antibodi
min
c
thereaft
cell
assay
bind
igg
sera
obtain
ibd
patient
describ
fitc
conjug
antibodi
serv
posit
control
sera
ibd
patient
examin
detect
igg
hcmv
antigen
use
elisa
previous
describ
sundqvist
et
al
sera
hcmv
posit
neg
healthi
blood
donor
use
control
sera
investig
presenc
igg
antibodi
paraffin
embed
intestin
tissu
obtain
ibd
patient
immunohistochem
stain
perform
briefli
formalin
fix
tissu
embed
paraffin
section
deparaffin
xylen
treat
h
methanol
rehydr
seri
grade
alcohol
wash
pb
serolog
statu
detail
patient
sera
examin
use
elisa
igg
antibodi
specif
hcmv
sera
detect
patient
uc
patient
cd
healthi
blood
donor
autoantibodi
sera
examin
use
mous
cell
analyz
fac
cytotox
anti
autoantibodi
could
block
use
monoclon
antibodi
detect
hcmvigg
posit
patient
uc
cd
respect
cytotox
anti
antibodi
could
detect
patient
sever
uc
patient
sever
cd
proteinas
k
treatment
nonspecif
block
bsa
preced
immunostain
specimen
incub
horseradish
peroxidaseconjug
goat
anti
human
antibodi
dakopatt
min
rt
presenc
igg
immunoglobulin
detect
use
diaminobenzidin
dakopatt
section
counterstain
hematoxylin
mount
aquamount
dakopatt
paraffinembed
intestin
tissu
section
uninflam
part
intestin
resect
specimen
obtain
patient
intestin
cancer
use
control
data
given
mean
ae
sem
student
ttest
use
statist
analysi
p
p
consid
signific
intestin
tissu
section
obtain
patient
uc
cd
examin
presenc
igg
reveal
stain
differ
cell
type
mucosa
deeper
layer
intestin
endotheli
cell
inflammatori
cell
epitheli
cell
smooth
muscl
cell
visibl
uninflam
intestin
section
serv
control
fig
investig
sera
obtain
ibd
patient
contain
autoreact
antibodi
sera
test
bind
neutrophil
granulocyt
hpaec
without
block
antibodi
block
differ
cell
almost
complet
block
serum
reactiv
cell
antibodi
significantli
reduc
reactiv
fig
express
detect
use
monoclon
antibodi
fig
serum
sampl
preabsorb
mous
test
reactiv
mous
cell
control
cell
analyz
flow
cytometri
method
identifi
higher
level
reactiv
antibodi
sera
obtain
ibd
patient
mous
cell
express
compar
sera
control
group
fig
determin
block
mous
cell
use
f
ab
fragment
monoclon
antibodi
monoclon
antibodi
use
control
fig
use
elisa
igg
antibodi
specif
hcmv
detect
sera
patient
uc
patient
cd
healthi
blood
donor
tabl
cytotox
autoantibodi
block
monoclon
antibodi
detect
hcmvigg
posit
hcmvigg
neg
patient
uc
cd
respect
tabl
twenti
patient
sever
uc
patient
sever
cd
respond
convent
medic
treatment
underw
surgeri
group
patient
cytotox
autoantibodi
could
detect
patient
sever
uc
patient
sever
cd
patient
posit
cmvigg
except
one
patient
uc
patient
cd
cmvigg
neg
tabl
howev
nonsever
group
lower
level
antibodi
reactiv
transfect
mous
cell
could
detect
use
fac
reactiv
sera
separ
two
categori
high
low
mean
fluoresc
intens
mfi
fac
analysi
sera
analyz
cytotox
cell
neutrophil
granulocyt
cell
hpaec
fig
eight
sera
obtain
uc
patient
high
mfi
f
ab
fragment
monoclon
antibodi
sera
obtain
patient
uc
block
cytotox
approxim
cell
hpaec
neutrophil
granulocyt
nine
sera
obtain
patient
cd
cytotox
block
cell
cell
hpaec
neutrophil
granulocyt
compar
block
monoclon
antibodi
fig
furthermor
sera
obtain
ibd
patient
uc
patient
cd
patient
low
mfi
monoclon
antibodi
block
cytotox
sera
obtain
uc
approxim
cell
cell
hpaec
neutrophil
granulocyt
sera
obtain
patient
cd
cell
cell
neutrophil
granulocyt
hpaec
observ
antibodi
also
block
cytotox
cell
type
cell
hpaec
extent
observ
use
antibodi
fig
howev
neither
monoclon
antibodi
block
cytotox
differ
cell
type
examin
use
sera
obtain
healthi
blood
donor
fig
furthermor
treatment
differ
cell
type
cocktail
monoclon
antibodi
result
cell
lysi
presenc
complement
hcmv
infect
common
viru
infect
worldwid
sinc
viru
infect
world
popul
viru
persist
indefinit
within
host
primari
infect
current
view
peripher
blood
monocyt
constitut
major
site
viral
latenc
differenti
tissu
macrophag
result
stimul
cell
proinflammatori
cytokin
lead
hcmv
reactiv
product
infect
previou
studi
demonstr
patient
sever
refractori
ibd
test
posit
hcmv
igg
antibodi
seem
plausibl
observ
hcmv
complic
infect
bowel
result
hcmv
reactiv
rather
de
novo
infect
patient
pathogen
associ
ibd
hcmv
also
suggest
sever
investig
previous
observ
activ
hcmv
infect
patient
uc
patient
cd
wakefield
et
al
detect
hcmvdna
intestin
tissu
sampl
patient
uc
cd
respect
use
nest
pcr
assay
recent
homm
et
al
comput
search
medlin
embas
report
case
report
address
role
hcmv
ibd
patient
major
report
describ
patient
sever
attack
uc
receiv
corticosteroid
prolong
time
hcmv
recogn
toxic
dilat
present
patient
colectomi
perform
patient
mortal
rate
high
observ
group
patient
illustr
sever
diseas
report
case
comput
search
medlin
embas
identifi
new
case
report
demonstr
hcmv
infect
patient
ibd
indic
increas
observ
preval
hcmv
infect
among
ibd
patient
sever
investig
report
benefici
role
antivir
treatment
ibd
patient
howev
possibl
pathogen
role
hcmv
ibd
patient
still
unclear
need
investig
hcmv
infect
implic
develop
autoimmun
varieti
autoantibodi
associ
bone
marrow
solid
organ
transplant
recipi
observ
pose
question
whether
hcmv
induc
autoimmun
may
play
role
pathogenesi
ibd
previous
identifi
molecul
present
cell
type
suscept
hcmv
infect
vitro
also
provid
evid
potenti
cellular
receptor
viru
also
previous
describ
molecul
associ
hcmv
particl
appear
immunogen
bone
marrow
transplant
patient
bmt
clinic
hcmv
infect
found
autoantibodi
identifi
bmt
patient
chronic
graftversushost
diseas
exclus
patient
experienc
either
hcmv
diseas
hcmv
viremia
antibodi
appear
time
hcmv
detect
present
studi
detect
higher
level
autoantibodi
cytotox
effect
differ
cell
type
sera
obtain
fig
bind
human
sera
mous
cell
express
human
monoclon
antibodi
use
detect
mous
cell
cell
serum
sampl
preabsorb
obtain
patient
uc
cd
control
group
test
bind
mous
cell
control
cell
analyz
flow
cytometri
method
identifi
higher
level
antibodi
sera
patient
ibd
compar
control
group
b
patient
uc
cd
respect
importantli
sera
obtain
patient
uc
cd
even
mfi
also
cytotox
effect
differ
cell
type
sera
healthi
donor
never
exhibit
cytotox
effect
find
indic
antibodi
low
reactiv
express
mous
cell
differ
type
cell
hpaec
neutrophil
granulocyt
cell
cell
sera
obtain
control
group
like
repres
unspecif
reactiv
possibl
pathogen
role
studi
cytotox
autoantibodi
could
detect
cmvigg
posit
patient
uc
cmvigg
posit
patient
cd
cytotox
autoantibodi
could
detect
one
four
cmvigg
neg
patient
uc
three
seven
cmvigg
neg
patient
cd
interestingli
cytotox
autoantibodi
could
detect
patient
sever
uc
patient
sever
cd
underw
surgic
treatment
pathophysiolog
role
antibodi
present
unknown
may
play
pathogen
role
sinc
antibodi
commonli
found
patient
sever
inflamm
suggest
autoantibodi
format
result
tcell
activ
clone
specif
hcmv
deriv
viral
peptid
antigen
present
cell
could
result
activ
reactiv
nontoler
b
cell
taken
contain
hcmv
particl
lead
process
present
viral
peptid
associ
hla
class
ii
molecul
stimul
helper
cell
result
product
antibodi
principl
activ
specif
autoimmun
respons
select
virusassoci
host
protein
may
oper
ibd
well
autoimmun
diseas
type
diabet
rheumatoid
arthriti
multipl
sclerosi
vascul
may
associ
viral
infect
presenc
autoantibodi
cmv
neg
patient
unknown
autoantibodi
may
also
develop
consequ
viral
infect
support
hypothesi
identifi
receptor
certain
coronavirus
interestingli
yeager
et
al
fig
cytotox
reactiv
sera
obtain
ibd
patient
differ
cell
type
eight
sera
obtain
uc
patient
mfi
high
monoclon
antibodi
sera
obtain
patient
uc
block
cytotox
approxim
cell
cell
hpaec
neutrophil
granulocyt
nine
sera
obtain
patient
cd
mfi
high
cytotox
block
cell
cell
hpaec
neutrophil
granulocyt
compar
block
monoclon
antibodi
a
sera
obtain
ibd
patient
uc
patient
cd
patient
mfi
low
monoclon
antibodi
block
cytotox
sera
obtain
uc
approxim
cell
cell
hpaec
neutrophil
granulocyt
sera
obtain
patient
cd
cell
cell
neutrophil
granulocyt
hpaec
cell
type
cell
hpaec
antibodi
also
block
cytotox
extent
observ
use
antibodi
a
neither
monoclon
antibodi
block
cytotox
differ
cell
type
examin
use
sera
obtain
healthi
blood
donor
a
report
novel
coronaviru
identifi
caus
agent
sever
acut
respiratori
syndrom
sar
found
hematolog
find
sar
patient
may
relat
direct
infect
blood
cell
bone
marrow
stromal
cell
via
andor
induct
autoantibodi
immun
complex
may
result
damag
cell
unfortun
author
investig
occurr
autoantibodi
perhap
coronavirus
unknown
virus
may
involv
induct
autoantibodi
certain
individu
unfortun
data
regard
viral
infect
patient
group
result
cytotox
assay
show
differ
cytotox
effect
autoantibodi
differ
cell
type
observ
differ
level
express
differ
cell
type
data
shown
observ
may
instead
explain
factor
eg
differ
distribut
complement
activ
complement
inhibitori
factor
eg
differ
cell
type
autoantibodi
may
differ
way
contribut
pathophysiolog
ibd
react
differ
cell
type
perhap
stimul
differ
effector
mechan
antibodymedi
tissu
injuri
instanc
antibodi
could
antibodi
depend
cellular
cytotox
phagocytosi
opson
cell
complement
mediat
cell
lysi
complementfc
receptor
mediat
leukocyt
recruit
lead
enhanc
inflamm
result
releas
enzym
reactiv
oxygen
speci
lead
increas
tissu
injuri
furthermor
enzymat
activ
aminopeptidas
n
may
also
crucial
import
normal
cell
physiolog
aminopeptidas
catalyz
cleavag
amino
acid
amino
terminu
protein
peptid
substrat
demonstr
play
role
trim
antigen
peptid
present
major
histocompat
complex
mhcii
also
suggest
modul
cell
cycl
occup
activ
center
artifici
ligand
monoclon
antibodi
induc
prolong
cell
cycl
decreas
rate
cell
growth
antibodi
may
also
caus
nonimmunolog
damag
target
cell
eg
induc
apoptosi
addit
molecul
impli
mediat
control
cellular
differenti
recent
found
hcmv
particl
interact
molecul
monocyt
lead
inhibit
macrophag
differenti
therefor
bind
antibodi
cell
structur
express
could
perhap
also
contribut
tissu
damag
chronic
inflamm
conclus
number
report
describ
hcmv
activ
ibd
patient
increas
provid
evid
autoimmun
ibd
patient
autoantibodi
previous
observ
hcmvinfect
patient
autoantibodi
may
pathogen
role
intestin
ibd
patient
specif
target
attack
posit
tissu
structur
may
also
explain
immunolog
phenomena
involv
bowel
eg
manifest
eye
joint
skin
observ
patient
identif
immunogen
elicit
specif
antibodi
respons
could
offer
new
clue
pathogenesi
ibd
may
provid
new
possibl
develop
specif
therapi
